The long-term tolerability of linezolid is low because of mitochondrial toxicity, whereas tedizolid may represent a better option for suppressive therapy. We report a first presumed case of tedizolid-associated optic neuropathy after a very prolonged (18-month) intake and believe that screening for optic neuropathy should be considered for patients undergoing tedizolid suppression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425497PMC
http://dx.doi.org/10.1093/ofid/ofae517DOI Listing

Publication Analysis

Top Keywords

optic neuropathy
12
suppressive therapy
8
severe optic
4
neuropathy induced
4
induced prolonged
4
prolonged tedizolid
4
tedizolid suppressive
4
therapy description
4
description case
4
case report
4

Similar Publications

Background: Proton beam therapy (PBT) has been gradually introduced for treating choroidal melanoma. This study systematically reviewed clinical reports to evaluate the efficacy and safety of PBT in choroidal melanoma patients.

Methods: This systematic review included all the primary studies involving PBT for choroidal melanoma patients through April 2024.

View Article and Find Full Text PDF

Optic Nerve Head Changes in Acute Central Serous Chorioretinopathy: Implications for Glaucoma Risk.

Photodiagnosis Photodyn Ther

January 2025

Istanbul Medeniyet University, Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey. Electronic address:

Objective: Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optic coherence tomography (EDI-OCT).

Methods: A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18-65 years.

View Article and Find Full Text PDF

Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.

View Article and Find Full Text PDF

Stem Cell-Based Therapies for Glaucoma Treatment: A Review Bridging the Gap in Veterinary Patients.

Int J Mol Sci

December 2024

Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto (UP), Praça Gomes Teixeira, Apartado 55142, 4051-401 Porto, Portugal.

Retinal diseases are characterized by progressive damage to retinal cells, leading to irreversible vision loss. Among these, glaucoma stands out as a multifactorial neurodegenerative disease involving elevated intraocular pressure, retinal ganglion cell apoptosis, and optic nerve damage, ultimately resulting in blindness in both humans and dogs. Stem cell-based therapies have emerged as a promising therapeutic option for such conditions due to their regenerative and neuroprotective potential.

View Article and Find Full Text PDF

Purpose: A relative afferent pupillary defect (RAPD) is a characteristic clinical sign of optic neuritis (ON). Here, we systematically evaluated ultrasound pupillometry (UP) for the detection of an RAPD in patients with ON, including a comparison with infrared video pupillometry (IVP), the gold standard for objective pupillometry.

Materials And Methods: We enrolled 40 patients with acute (n = 9) or past (n = 31) ON (ON+), 31 patients with multiple sclerosis (MS) without prior ON, and 50 healthy controls (HC) in a cross-sectional observational study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!